Evidence review
Coming Off a GLP-1: Maintenance, Rebound Weight, and How to Keep It Off
Most of the weight comes back when you simply stop — and that's biology, not failure. What the withdrawal trials show and how mothers plan around it.
Elena Voss is a mother writing for mothers, not a treating clinician. The evidence in this piece was checked against its primary sources by Grant Okonkwo, a former pharmaceutical-industry analyst — Elena and Grant hold no medical license, and this is background reading, not medical advice.
On this page
The short version
The single most important thing to know before you stop a GLP-1 is that stopping cold tends to bring the weight back — and that this is the drug wearing off, not you failing. In the pivotal semaglutide trial's extension, participants who came off the drug regained about two-thirds of the weight they had lost within a year, and much of the metabolic improvement reversed alongside it2. That's not a reason to feel trapped; it's a reason to treat coming off as a plan rather than an event. For a mother, that plan has real forks in it — a pregnancy you're timing toward, a cost or coverage change, or simply wanting to test whether you can hold the result — and each fork has a smarter and a rougher way through.
This is educational only, not medical advice. But the data here are unusually clear, and knowing them changes how you'd stop.
Why the weight comes back: it's the biology, not willpower
GLP-1 medications work while they're in your system by turning down appetite and slowing gastric emptying. Take the drug away and that appetite suppression goes with it — hunger signals return, and the body's strong drive to defend its prior weight reasserts itself. The trials show this plainly. When semaglutide was stopped and switched to placebo in the STEP 4 design, the group that came off began regaining while the group that continued kept losing3. In the STEP 1 extension, a year after treatment and lifestyle support ended, participants had regained roughly two-thirds of their lost weight2. Tirzepatide behaves the same way: in SURMOUNT-4, people randomized to withdraw the drug regained substantial weight, while those who continued it maintained and even extended their loss4. Across both molecules, the message is identical — continued treatment maintains the result; stopping reverses much of it. That reframes obesity treatment as ongoing, more like managing blood pressure than finishing a course of antibiotics.
The honest baseline: what you're maintaining
It helps to remember the size of what's on the table. Semaglutide produced about 15% average weight loss in its pivotal trial1, and the two-year STEP 5 data showed that loss was sustained while treatment continued5. So the realistic framing isn't "lose it and be done." It's "reach a weight, then decide how to hold it" — and the evidence says the most reliable way to hold it is some form of continued treatment, not a hard stop.
The maintenance options mothers actually use
"Continue" doesn't have to mean the full dose forever. In practice there are a few paths, and the right one is a clinician conversation, not a rule:
- Stay on a maintenance dose. Many people hold their weight on the dose that got them there, or a step below it. This is the best-supported approach.
- Taper toward the lowest effective dose. Some find a lower dose still holds the result with fewer side effects — the same logic behind microdosing GLP-1s. It's individual, and worth doing under supervision rather than by guesswork.
- Stop deliberately, with scaffolding. If you do come off — for a pregnancy, cost, or personal reasons — go in expecting appetite to return and lean hard on the levers that don't wear off: protein at every meal, resistance training to protect muscle and bone, sleep, and structure. These won't fully match the drug, but they blunt the slope.
The mother-specific reason to plan the exit
For many mothers the trigger to stop isn't weight at all — it's a pregnancy. GLP-1s aren't used in pregnancy and linger about a week per dose, so conceiving means a planned washout well before you start trying. That makes "how do I come off, and what happens when I do" a question you'll likely face on someone else's timeline. Thinking it through in advance — including whether you'll restart afterward — beats improvising. Our guides on GLP-1s and breastfeeding and birth control on a GLP-1 cover the reproductive-timing pieces that sit next to this decision.
Restarting, and switching, are normal
Coming off isn't a one-way door. If you stop for a pregnancy and want to restart after weaning, that's a routine re-titration, not starting from zero psychologically. And if the question is really "which molecule holds best for me," the maintenance data favor staying on a GLP-1 over stopping either one — our semaglutide vs tirzepatide for mothers and Zepbound vs Wegovy guides compare them, including on how each behaves when you continue versus stop.
How to actually decide
Rebound weight is predictable physiology, which means it's also plannable. The reliable path is continued treatment at whatever the lowest dose is that holds your result, with a real taper or stop plan when life requires one — and honest support around it. That kind of long-horizon, maintenance-minded care is exactly what our Metabolic-Fit Score methodology rewards, and why clinician-led programs such as CoreAge Rx rank near the top of our best-value GLP-1 board; some links here earn us a referral fee. Bring your history, your budget, and your pregnancy plans to a clinician and build the exit before you need it. This article is educational only and not medical advice.
Frequently asked questions
Will I regain the weight if I stop a GLP-1?
Usually much of it, yes — and it's the drug wearing off, not a personal failure. In the STEP 1 extension, people who stopped regained about two-thirds of their lost weight within a year, and the metabolic gains reversed too. Tirzepatide behaves the same way. The reliable way to hold the result is continued treatment, which is why clinicians increasingly treat obesity as ongoing rather than a one-time course.
Do I have to stay on the full dose forever to keep it off?
Not necessarily. Many people maintain on the dose that got them there or a step below, and some hold their result on a lower dose with fewer side effects. What the evidence discourages is stopping cold and hoping — that's what drives rebound. The right maintenance dose is a supervised, individual decision.
I need to stop for a pregnancy — how do I limit the rebound?
Plan it. GLP-1s aren't used in pregnancy and linger about a week per dose, so you'll wash out before trying to conceive. Go in expecting appetite to return, and lean on the levers that don't wear off — protein at every meal, resistance training to protect muscle, sleep, and structure. They won't fully replace the drug, but they blunt the regain, and restarting after weaning is routine.
References
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
- Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/36216945/
Background reading, not medical advice. MomMetabolic summarizes published research and FDA labeling for mothers weighing GLP-1 care. It cannot diagnose you, cannot account for your history or hormones, and is no substitute for a licensed clinician who can. Decisions to begin, adjust, pause, or stop any medication belong with your own prescriber.
Continue reading
GLP-1s and Antidepressants: What Mothers on an SSRI Should Know
Is it safe to take a GLP-1 with an SSRI? The interaction question, the additive nausea, the mental-health safety data, and what to tell your prescriber.
ReadSemaglutide vs Tirzepatide for Mothers
The head-to-head data, the maintenance question, and the mother-specific details — contraception, timing, cost — that a molecule headline never captures.
ReadMicrodosing GLP-1s for Mothers: What the Evidence Says
What microdosing a GLP-1 actually means, what the dose-response data show, who it might suit — and the honest gap: no trial has tested it.
Read